ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Is Cervical Cancer Screening a necessary part of HIV care in Zimbabwe? ZIMA Congress Friday 29 th August.

Slides:



Advertisements
Similar presentations
HPV Testing and Genotyping
Advertisements

Repositioning Prevention and Control of Cancers of Reproductive Organs in Kenya Repositioning Prevention and Control of Cancers of Reproductive Organs.
STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
Cervical Screening and HPV testing
MANAGEMENT OF THE ABNORMAL PAP SMEAR
Cervical Cancer. Dr. Swapna Chaudhary M.S. (MUM) Consultant Obstetrician & Gynaecologist Infertility Specialist.
Cervical Cancer DR KHALID H. WALI SAIT (FRCSC) ASSOCIATE PROFESSOR OF GYNECOLOGICAL ONCOLOGY King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Treatment Options for CIN Cervical Cancer screening is designed to detect CIN If CIN is present treatment should theoretically avoid subsequent cancer.
Somaiya Medical College and Maina Foundation Five Year Project for Raising breast Cancer Awareness in Pratikshanagar - Mumbai.
ASHLYN SAVAGE, MD, MSCR ASSOCIATE PROFESSOR OBSTETRICS AND GYNECOLOGY MEDICAL UNIVERSITY OF SOUTH CAROLINA Managing Abnormal Pap Smears: Incorporating.
Cervical Cancer and HPV Z Mike Chirenje MD FRCOG University of Zimbabwe, Department of Obstetrics and Gynecology, Harare, Zimbabwe.
M. Munjoma. Outline Burden of HPV Disease HPV in Zimbabwe HPV Lab Development HPV Protocols.
Cervical Cancer Cervical dysplasia Cervical cancer Causes Risk factors
HPV and cervical screening Test of cure
Benign and premalignant disease of the cervix
Cervical Cancer and HIV: Interactions and Interventions Jean R. Anderson, M.D. Jhpiego, an affiliate of Johns Hopkins University The Johns Hopkins University.
Anticipated impact on HPV infection from HPV vaccination programs – cause for optimism Dr Paddy Horner.
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
MINISTRY OF HEALTH Cervical Cancer in Kenya Presentation to the Cancer workshop – KNH 13 th April 2012 Dr Nancy Kidula.
Cervical Cancer Screening
Screening Tests for Brest & Cervical Cancer
Review of the Guidelines for Cervical Screening in New Zealand Presentation for smear-takers September 2008.
HIV in Suriname Ministry of Health Suriname M.Sigrid Mac Donald – Ottevanger, MD Focal point HIV Treatment and Care, NAP.
Screening for Cervical Cancer by Visual Inspection Techniques Dr Aruna Batra VMMC & SJH.
CANCER CERVIX A PREVENTABLE CANCER Dr NEETA DHABHAI Sr Consultant. – Gynaecologist Member Expert - Indian Cancer Winners’ Association
What Is HPV? Human Papillomaviruses have an icosahedral shape, contain DNA, and are non-enveloped There are at least 100 different types of HPV Over 30.
VIA Screen-and-Treat Cervical Cancer Prevention in Guyana: A Mobile Clinic Pilot Project to a Remote Amerindian Community John E. Varallo, MD, MPH, FACOG.
Overview of NHS Cervical Screening Programme Cervical Screening QARC Training School October 2012.
Epidemiology of a Chronic Disease Exercise By Mary Murphy April 2008
Screening for cervical cancer. Screening for cervical lesions Common disease Cancer is preventable Screening is easy MUST BE PERFORMED.
HPV VACCINATION Dr Frida Mghamba 2 nd East Africa WE CAN Summit 11 th September 2014.
Nursing Process HPV.
Cervical Intraepithelial Neoplasm
Adult Medical-Surgical Nursing
TEMPLATE DESIGN © Outcome of Large Loop Excision of Transformation Zone (LLETZ ) in women over forty at two London Hospitals.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
The National HIV Counselling and Testing Campaign and Treatment Expansion in South Africa: A return on investments in combination prevention XIX International.
Cervical Cancer. Female Gynecologic Cancers Cervical Cancer.
Dr. Phimpha Paboriboune, Scientific Director,
SEXUAL HEALTH: SCREENING, VACCINES AND REFERRALS Dr Kate Morton.
Integration of HIV/AIDS and Cervical Cancer Programs for Improved Health Outcomes in Tanzania Dr. January Zilabumba IMA World Health 30 November, 2015.
Premalignant lesions of the cervix. Applied anatomy.
NHS Cervical Screening Programme Introducing HPV triage and test of cure.
HPV and Pap Guidelines Jennifer Johnson MD. Objectives 1. Define the new PAP guidelines. 2. Identify the historical trends and new evidence resulting.
HPV AND WOMEN’S CANCER A.C. Evans. M.D., Ph.D.. HPV and Women’s Cancer I have no relevant financial relationships with the manufacturer(s) of any commercial.
Cervical Cancer How We Can Prevent It Dr Quek Swee Chong Himalayan Women’s Health Project 30 August 2014.
HPV-related anogenital cancers
Cervical Cancer: Experiences from a Cohort of HIV-infected Women Pascoe M, Magure T, Mudhokwani P et al Abstract: MOAB0202.
CANCER OF THE CERVIX SCREENING AND EARLY TREATMENT Dr Nelly R. Mugo MBchB, MMED, MPH Dr Rose J. Kosgei MBchB, MMED, Msc Kenyatta National Hospital: Department.
HIV & HPV Co-infections: Clinical Presentation & Management
#AIDS2016 Cervical Cancer Prevention in Africa: The Future Nelly Yatich, DrPH University of California San Francisco July 19 th, 2016.
Cervical cancer screening and treatment among HIV+ women in Cambodia: feasible and high yielding M.-E. Raguenaud 1, P. Isaakidis 1, S.A. Khim 1, C. Ping.
Public Health England leads the NHS Screening Programmes
Cancer prevention and early detection
NHS Cervical Screening Programme Introducing HPV Triage
Cancer prevention and early detection
Cancer prevention and early detection
INTRODUCTION: CERVICAL CANCER SCREENING
Treatment Options for Cervical Cancer in Low Income Countries
Cervical Cancer Colposcopy & Treatment
Risk factors for cervical intraepithelial neoplasia recurrence after loop electrosurgical excision procedure in HIV-1-infected and non-infected women.
Obstetrician and Gynecologist Malawi Inaugural Cancer Symposium
Nasreen Abdullah, MD, MPH
SBÜ KAYSERİ ERH Doç. Dr. Gökhan Açmaz
Public Health England leads the NHS Screening Programmes
Cervical Screening for Dysplasia and Cancer in Patients with HIV
Screening to Prevent Invasive Cervical Cancer (Resource-Stratified)
Presentation transcript:

ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Is Cervical Cancer Screening a necessary part of HIV care in Zimbabwe? ZIMA Congress Friday 29 th August

Presentation Outline Newlands Clinic and WHS Case studies HPV and HIV Methodology and results Conclusion Recommendations 2

The Newlands Clinic (NC) A Public Private Partnership with AIDS & TB unit in MOHCC Commenced operations in 2004 offering free, comprehensive HIV care & treatment for over 5000 patients: lab & pharmacy, diagnosis & management of OIs including TB, women’s health service (WHS), pyscho-social programme, adolescent corner & a nutrition programme Nurse-led model of care 3

The Newlands Clinic (NC) Training school: o National Advanced HIV Management for Adults & Children o Visual Inspection with Acetic Acid & Cryotherapy (VIAC) training Partner in the National VIAC programme 4

The Newlands Clinic WHS Launched in January 2011 to offer cervical cancer screening, STI diagnosis & treatment for all sexually active female patients registered at NC Currently 2550 females > 18 years of age in care Nurse-led service supervised by Dr Magure (UZ Dept O&G) 5

The Newlands Clinic WHS ‘See & treat’ approach – VIAC & cryotherapy Loop Electrosurgical Excision Procedure (LEEP) for more advanced lesions Referral system for patient’s requiring complicated surgical procedures eg TAH 6

The NC WHS Equipment Gynae couch Light Cryogun Gas cylinder and stand + spare Camera plus accessories Monitor Trolley Sterile packs Stool Patient information Vinegar Computer + software

Screening for Cervical Abnormality Cytology (pap smear) Visual methods (VIAC, VILI) HPV DNA testing – screen for high risk HPV types, not recommended for routine practise

Normal Cervix

VIA Positive

VIAC Positive

Invasive cervical cancer

Case Study 1 – Mrs EC 49 years old Commenced ART in January 2005 (9½ years) On 1 st line (TDF/3TC/NVP) Baseline CD4 count 83, June Viral load undetectable since April

Mrs EC - routine VIAC screening in April LEEP:histology - koilocytosis VIAC positive: eligible for LEEP

Mrs EC – VIAC screening April VIAC positive - eligible for LEEP Histology – micro-invasive carcinoma of the cervix

Mrs EC - outcome TAH done at Karanda Mission Hospital in Dec 2013 Histology confirmed micro-invasive carcinoma of the cervix Reviewed in WHS June 2014 – all well For repeat VIAC (vaginal vault Dec 2014) 18

Case study 2 – Ms MM 19 year old Commenced ART in March 2005 (at 10 years of age) Baseline CD4 was 224, June 2014 was 710 Viral load undetectable 19

Ms MM – routine VIAC screening August VIAC positive – eligible for LEEP LEEP done 13/08/2014 – CIN I

HIV, HPV and Cervical Cancer >140 HPV types identified, 40 infect female genital tract & 18 (incl types 16 & 18) are high risk for oncogenesis Pre-existing HPV infection is associated with a 2-fold increase in the risk of HIV acquisition in women (1) It has been recognized that HIV+ve people: - more likely to have HPV - carry ↑ number of HPV types - less likely to spontaneously clear HPV infection

HIV changes the natural history of HPV infection → 10 fold ↑ incidence of cervical dysplasia & 5 fold ↑ incidence of cervical neoplasia HIV causes chronic inflammation – markers present in blood and urine (2) Recurrence rates of HPV infection are higher in HIV+ve women than in HIV-ve women HIV+ve women with a low CD4 count are more likely to experience progression of cervical cancer ARV’s will prolong the life of women infected with HPV & allow the development of cervical cancer HPV infection in HIV+ve Women

The most common types of lower genital tract disease caused by HPV infection in HIV+ve women: Cervical intraepithelial neoplasia (CIN) Genital warts Vulval intraepithelial neoplasia Anal intraepithelial neoplasia Vaginal intraepithelial neoplasia Cervical cancer Anal cancer 23

Purpose of the record review The purpose of this review was: To establish the prevalence of VIAC positive lesions at initial screening in women registered in care at NC To determine the histological diagnosis in women with VIAC positive lesions undergoing the LEEP procedure 24

Methodology A record review of patients undergoing initial cervical screening from January 2011 to December 2013 was done The percentage of VIAC positive lesions was assessed Histological specimens obtained from 235 LEEP procedures were analysed 25

Results The age range of women with VIAC positive lesions screened was 18 – 63 years The % of women with VIAC positive lesions was: % (314/899) % (269/895) % (126/406) The mean over the 3 years was 32.0% 26

Results Histological diagnosis for 235 LEEP specimens confirmed pre-cancerous lesions in 69% CIN I - 12% CIN II - 27% CIN III - 30% Cervical cancer in 2% 27

Histological Diagnosis 28 CIN I 12% CIN II 27% CIN III 30% HPV-related changes 17% Cervical Cancer 2% Other 12%

Conclusions These data illustrate a 32% prevalence of VIAC positive lesions Histological diagnosis confirmed moderate to severe dysplasia (CIN II and III) in 57% and invasive cancer in 2% Cervical screening, plus appropriate treatment, is an essential component of care for HIV-infected women in care at Newlands Clinic 29

30

Recommendations VIAC must be introduced as standard of care for all HIV+ve women in Zimbabwe In order to prevent HPV infection & consequent cervical disease, pre-adolescent girls must be vaccinated (3) Due to the parallel epidemics of HPV & HIV in Zimbabwe, we should consider HPV vaccination as a additional preventive strategy for pre-adolescent girls, in an attempt to reduce the acquisition of HIV in this key population (3)

32

References 1. CF Houlihan, NL Larke, D Watson-Jones, et al. HPV infection and increased risk of HIV acquisition: a systematic review and meta-analysis. XIX International AIDS Conference (AIDS 2012). Washington, DC, July 22-27, Poster WEPE258.Poster WEPE The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels. Fitzgerald DWFitzgerald DW, Bezak K, Ocheretina O, Riviere C, Wright TC, Milne GL, Zhou XK, Du B, Subbaramaiah K, Byrt E, Goodwin ML, Rafii A,Dannenberg AJ.Bezak KOcheretina ORiviere CWright TCMilne GLZhou XKDu BSubbaramaiah KByrt EGoodwin MLRafii ADannenberg AJ 3. J Brotherton, M Fridman, CL May, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377(9783): (abstract). June 18, 2011.abstract

Thank you The women in care at NC The staff in the NC WHS Dr Magure Prof Luethy To you all for listening! 34